Wednesday, June 12, 2013
8:30 a.m. – 12:30 p.m.
Boston Convention & Exhibition Center (BCEC)
Boston, MA  USA

This session is open to all registered meeting delegates and is included with your registration. No pre-registration is required.

New Concepts and Tools for Advancing Stem Cell Research and Therapeutic Approach

 
   
Presented by Thermo Fisher Scientific

Stem cell research has emerged as one of the most promising areas of medical science, attracting unprecedented public support and interest.  In line with our company’s commitment to advancing stem cell research, scientists from Thermo Fisher Scientific will present its newest culture systems for generating, expanding, characterizing, and preserving stem cells.  The significant savings in labor and cost, coupled with the above-industry-standard performance of the systems, will result in meaningful outcomes in the core of your daily research.  In addition, speakers from industry and academia will exchange ideas about their recent discoveries. 

Agenda

8:30 am – 9:15 am

Reagents for microRNA Functional Analysis in Stem Cells.  Emily Anderson, Ph.D., Senior Scientist, Gene Modulation, Thermo Fisher Scientific

9:15 am – 9:45 am

Optimized expansion and characterization of human pluripotent stem cells without compromising pluripotency.  Amy Sinor-Anderson, Ph.D., Senior Research Scientist, Labware and Specialty Plastics, Thermo Fisher Scientific

9:45 am – 10:30 am

Past problems and future challenges of human pluripotency.  Hidemasa Kato, Ph.D., Saitama Medical University, Research Center for Genomic Medicine

10:30 am – 11:15 am

Support cell therapy for CNS: Reprograming for Repair.  Chris Pröschel, Ph.D., University of Rochester Medical Center, Department of Biomedical Genetics

11:15 am – 11:45 am

The design and capabilities of the Upstate Stem Cell cGMP Facility.  Michael J. Fiske, M.S., Executive Director, Upstate Stem Cell cGMP Facility, University of Rochester Medical Center

11:45 am – 12:30 pm

Cold-chain & logistical challenges of cell-based therapies in clinical trials through commercialization.  Dan O’Donnell, Associate Director, Cell Therapy Logistics, Fisher BioServices

 Learning objectives and goals of the symposium

  • New tools to manipulate endogenous mature microRNA function in stem cells with rationally designed synthetic and expressed microRNA modulation reagents
  • New tools to improve proficiency in culturing human pluripotent stem cells
  • Discovery of degradation mechanism for a cellular enzyme TET1 in hiPSC and the effect of its over-expression on human pluripotency and disease modeling
  • Novel concept in functional heterogeneity of astrocyte populations and the role of a unique population of astrocytes in repairing injuries to the central nervous system (CNS)
  • From research to therapy – building a cGMP-compliant stem cell facility
  • Forward thinking in packaging, distribution, and logistical requirements for cell-based drug phase II and phase III clinical trial design

Target audience

Scientists and researchers from academia, industry and government research whose work involves cell biology and stem cell research.